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Depression is the most common psychiatric disorder worldwide. The burden of disease for depression goes beyond
functioning and quality of life and extends to somatic health. Depression has been shown to subsequently increase
the risk of, for example, cardiovascular, stroke, diabetes and obesity morbidity. These somatic consequences could
partly be due to metabolic, immuno-inflammatory, autonomic and hypothalamic-pituitary-adrenal (HPA)-axis
dysregulations which have been suggested to be more often present among depressed patients. Evidence linking
depression to metabolic syndrome abnormalities indicates that depression is especially associated with its obesity-
related components (for example, abdominal obesity and dyslipidemia). In addition, systemic inflammation and
hyperactivity of the HPA-axis have been consistently observed among depressed patients. Slightly less consistent
observations are for autonomic dysregulation among depressed patients. The heterogeneity of the depression
concept seems to play a differentiating role: metabolic syndrome and inflammation up-regulations appear more
specific to the atypical depression subtype, whereas hypercortisolemia appears more specific for melancholic
depression. This review finishes with potential treatment implications for the downward spiral in which different
depressive symptom profiles and biological dysregulations may impact on each other and interact with somatic
health decline.
Keywords: Depression, Metabolic syndrome, Inflammation, Cortisol, Autonomic Tone, Cardiovascular, Obesity,
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Introduction
Depressive feelings are a normal component of distress
or grief. When depressive feelings turn into a chronic,
disabling disorder interfering with daily life, a clinical
diagnosis of major depressive disorder (MDD or shortly
termed depression) ensues. Depression refers to a range
of mental problems characterized by loss of interest and
enjoyment in ordinary experiences, low mood and associ-
ated emotional, cognitive, physical and behavioral symp-
toms. Depression is one of the most prevalent diseases
globally: 6% of the population meets the MDD criteria at a
specific time point. During a lifetime, depression affects* Correspondence: b.penninx@vumc.nl
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reproduction in any medium, provided the orone out of every six adults with women being affected
twice as often as men [1]. Currently, depression is the
third leading contributor to the global disease burden, but
will rise to a first-place ranking by 2030 [2]. This is largely
due to the facts that depression is common, has a major
impact on functioning and quality of life, and affects
persons often in early life and for sustained periods,
thereby causing many disease years. Consequently, de-
pression largely affects public health and involves high
societal costs.Somatic consequences of depression
The impact of depression on health extends beyond
quality of life and functioning outcomes. Over the last
20 years, many studies illustrated the impact of depres-
sion on incident somatic disease development. Table 1
summarizes meta-analyses integrating evidence from
longitudinal studies conducted among initially disease-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Meta-analyses examining the association between depression and incidence of mortality or morbidity in
disease-free subjects
Incident event Reference Nr studies included Nr subjects included Pooled risk (95% CI) of depression
Overall mortality Cuijpers et al. [5] 25 106,628 1.81 (1.58 to 2.07)
Heart disease Nicholson et al. [3] 21 124,509 1.81 (1.53 to 2.15)
Hypertension Meng et al. [12] 9 22,367 1.42 (1.09 to 1.86)
Stroke Dong et al. [13] 17 206,641 1.34 (1.17 to 1.54)
Diabetes Mezuk et al. [4] 13 212,019 1.60 (1.37 to 1.88)
Alzheimer’s disease Gao et al. [14] 4 5,656 1.66 (1.29 to 2.14)
Obesity (BMI ≥30) Luppino et al. [15] 9 6,436 1.58 (1.33 to 1.81)
Cancer Chida et al. [16] 25 n.a. 1.29 (1.14 to 1.46)
BMI, Body mass index; CI, Confidence interval; n.a., Not available.
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that depression increases the risk of overall mortality
(RR = 1.81) and the development of cardiovascular-
related outcomes, such as heart disease (RR = 1.81),
diabetes (RR = 1.60), hypertension (RR = 1.42), stroke
(RR = 1.34) and obesity (RR = 1.58). Meta-analyses also
indicate that depression increases the risk of developing
Alzheimer’s disease (RR = 1.66) and to a lesser extent
even cancer (RR = 1.29). Most meta-analyses have been
based on longitudinal studies using depressive symptom
checklists which pick up many subthreshold depression
cases. However, the increased somatic morbidity has also
been found in patients fulfilling psychiatric diagnostic
criteria, who - in line with a dose–response association -
have slightly higher incident morbidity rates [3-5]. The ob-
served increased somatic risks associated with depression
are substantial. For instance, the 81% increased risk for
cardiovascular disease onset is very similar to that ob-
served for well-established risk factors, such as obesity [6],
metabolic syndrome [7], low high-density lipoprotein
(HDL) cholesterol [8] or high C-reactive protein (CRP)
[9]. Recently, the Global Burden of Disease project
listed depression as one of the main contributors to dis-
ability (2nd rank [10]) and diminished active life expect-
ancy (11th rank [11]). If one would have been able to take
the negative impact of depression on somatic morbidity
into consideration, the estimated negative contribution of
depression to public health would be even larger.
Meta-analyses on somatic consequences of depression
have reported pooled effect sizes for adjusted associa-
tions which considered potential confounding variables
such as lifestyle indicators. Depressed persons are on
average unhealthier; they are more likely to smoke, drink
excessive amounts of alcohol, eat an unhealthy diet and
be more physically inactive than non-depressed peers
[17]. Many - but not all - of the conducted studies asso-
ciating depression to incident medical morbidity have
tried to adjust for life style differences. These lifestyle
adjusted pooled effect sizes are only slightly lower than
unadjusted ones, suggesting that the increased morbidityrisks are not simply due to lifestyle differences. However,
considering the fact that, for example, nutritional and
physical activity patterns are not easy to assess in detail
in large-scale observational studies, residual impact of
these behavioral factors may still exist. In addition,
poorer self-care and poorer compliance with general
health regimens have been reported among depressed
persons [18] and may add to the found link between de-
pression and somatic disease development. Alternative
explanations for the link between depression and in-
creased morbidity development could be underlying fac-
tors that explain both outcomes rather independently,
such as low socio-economic status, childhood maltreat-
ment or shared genetic effects (genetic pleiotropy).
In addition to the above provided explanations,
depression-related biological dysregulations that also
constitute risk factors for somatic illnesses could further
contribute to the observed depression and somatic dis-
ease link. The next section describes evidence for bio-
logical dysregulations examined in this context. It
should be emphasized that within the realm of this
paper we are not able to delineate in much detail all po-
tential underlying biological dysregulations linking de-
pression to somatic illnesses. We focused on the most
commonly examined biological dysregulations in this
respect, namely metabolic, immuno-inflammatory, auto-
nomic and hypothalamic-pituitary-adrenal (HPA)-axis
dysregulations.
Biological dysregulation linking depression to somatic
health
Metabolic dysregulation
Often clinical metabolic dysregulations are assessed in the
context of the metabolic syndrome: a cluster of general
metabolic risk factors including abdominal obesity, in-
creased blood glucose (hyperglycemia), elevated blood
pressure, increased triglycerides and decreased HDL chol-
esterol. Metabolic dysregulations are well-established risk
factors for the development of various somatic conditions,
including, for example, cardiovascular disease, diabetes,
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thereby being a potential linking mechanism between de-
pression and incident somatic conditions. Pan et al. [22]
systematically reviewed 29 cross-sectional studies and
found depression and the metabolic syndrome to be
modestly associated (unadjusted OR = 1.42; adjusted OR =
1.34). Some reviewed prospective studies confirmed a bi-
directional association with depression predicting the onset
of metabolic syndrome, which in turn predicted depression
onset over time. However, the metabolic syndrome is a
heterogeneous concept: pathophysiological mechanisms of
elevated blood pressure, dyslipidemia and hyperglycemia
are not necessarily similar. Therefore, various studies have
tested consistency of associations with depression across
different metabolic syndrome components. The most con-
sistent evidence exists for depression and obesity-related
components (abdominal obesity, low HDL cholesterol,
hypertriglyceridemia) [23-52]. Depression associations withTable 2 Overview of meta-analyses examining the cross-secti
depression status
Reference Nr studies inclu
Metabolic dysregulation
Metabolic syndrome Pan et al. 20121 [22] 29
Abdominal obesity Xu et al. 20111 [57] 15
Immuno-inflammatory dysregulation




Interleukin-6 Dowlati et al. 20102 [59] 16
TNF-α 13
Interleukin-1β 9





Heart rate variability Rottenberg, 20072 [61] 13
Heart rate variability Kemp et al. 20102 [62] 14
HPA-axis dysregulation
Higher cortisol 3 Stetler and Miller 20111 [63] 354
Higher ACTH 96
Higher CRH 16
Saliva morning cortisol Knorr et al. 20101 [64] 20
Saliva evening cortisol 10
ACTH, Adrenocorticotropin hormone; CI, Confidence interval; CRH, Corticotropin-rel
difference between depressed and non-depressed; OR, Odds ratio; TNF, Tumor necr
1 Included depressed cases based on self-report checklists or psychiatric diagnostic
2 Only included depressed cases conform to psychiatric diagnostic criteria.
3 Cumulative assessment of cortisol across body fluids and across various time poin
4 Did not include data from one study including 1,018 depression patients and 515hyperglycemia [25,27,28,37,39,41-47,50] and hypertension
were less often confirmed [28,32,47,53-56]. Also when evi-
dence from longitudinal studies was pooled, consistent
associations were only confirmed for the obesity-related
components [22]. This is in line with a recent meta-
analysis [57] which showed that abdominally obese persons
are at a 1.38 increased odds of having depression (Table 2).
One longitudinal study among depressed patients found
that a combination of multiple metabolic dysregulations
contributed to chronicity of depression [33]. Taken to-
gether, literature suggests that abdominal obesity and lipid
disturbances are the driving force behind the relationship
between depression and metabolic syndrome. Once both
are present, abdominal obesity might give rise to multiple
metabolic dysregulations, which in turn might be respon-
sible for remaining in a depressed state.
How could a link between metabolic dysregulation
and depression be explained? White adipose tissue,onal association between biological dysregulations and
ded Nr subjects included Pooled effect size (95% CI)
155,333 OR = 1.42 (1.28 to 1.57)
34,832 OR = 1.38 (1.22 to 1.57)
51,234 d = 0.15 (0.10 to 0.21)
24,837 d = 0.25 (0.18 to 0.31)
756 d = 0.35 (0.03 to 0.67)
1,214 d = 0.25 (0.04 to 0.46)
892 MD = 1.8 pg/mL (1.2 to 2.3)
788 MD = 4.0 pg/mL (2.2 to 5.7)
533 MD = −1.6 pg/mL (−3.6 to 0.4)
596 MD = 0.56 pg/mL (0.28 to 0.84)
923 MD = 0.68 pg/mL (0.44 to 0.92)
995 MD = 0.55 pg/mL (0.13 to 0.99)
580 MD = −0.53 pg/mL (−1.36 to 0.31)
686 d = 0.33 (0.18 to 0.49)
726 Hedges’ g = −0.21 (−0.40 to −0.02)4
18,374 d = 0.60 (0.54 to 0.66)
3,812 d = 0.28 (0.16 to 0.41)
888 d = −0.53 (−1.71 to 0.65)
2,318 MD = 2.6 nmol/l (1.0 to 4.2)
1,617 MD = 0.3 nmol/l (0.03 to 0.5)




controls that found a much smaller effect size (d = 0.12).
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organ producing inflammatory cytokines and hormones
(for example, leptin) and, therefore, a major contributor
to pathogenic immunometabolic responses linked to
metabolic diseases and depression. For instance, inflam-
matory factors stimulate the release of lipids in the
bloodstream to provide energy for host defense and
cause a reduction in HDL cholesterol [65]. Moreover,
obesity-related chronic inflammation is involved in the
development of insulin resistance through activation of
the inhibitor of kB kinase-β/nuclear factor-kβ (IKKβ/
NFkβ) complex [66]. Leptin is an anti-obesity hormone
regulating nutritional intake and energy expenditure. In
the central nervous system obesity-associated inflamma-
tion can disrupt leptin hypothalamic action through
IKKβ/NFkβ regulation of SOCS-3 (suppressor of cyto-
kine signaling-3), a key inhibitor of leptin signaling [67].
The resulting state of leptin central resistance, character-
ized by the failure of high levels of leptin to suppress
food intake and decrease adiposity, is a hypothesized
shared biological mechanism underlying obesity and de-
pression. Leptin receptors are expressed in limbic sub-
strates related to mood regulation, and in animal models
leptin exerts antidepressant behavioral effects [68]. Lep-
tin has also been shown to affect hippocampal and cor-
tical structure through its actions on neurogenesis, axon
growth, synaptogensis and dendritic morphology regula-
tion [69].
Another possible mechanism linking metabolic dys-
regulation and depression may be represented by
cerebrovascular damage associated with metabolic syn-
drome, which have been hypothesized to predispose
people to depression, especially in late-life [70]. Finally,
other depression-related biological dysregulations de-
scribed in this review may constitute shared underlying
pathways to metabolic alterations. For instance, adipose
tissue expresses a high density of glucocorticoid recep-
tors, and their binding with cortisol activates lipoprotein
lipase and inhibits lipid mobilization, leading to an accu-
mulation of triglycerides [71]. Similarly, sympathetic ner-
vous system overactivation is connected to high blood
pressure [72].
Immuno-inflammatory dysregulation
A consistent body of evidence indicates that depression
is associated with dysregulated inflammation, an im-
mune response that derives from activation of the innate
immune system. The inflammatory mediators’ network
is represented by a bewildering array of molecules, the
most prominent of which are proinflammatory cytokines
(for example, interleukin (IL)-1, IL-6 and tumor necrosis
factor (TNF)-α) produced within innate immune cells in
response to immunologic challenge. Other cytokines,
known as anti-inflammatory, oppose this response byattenuating the production of proinflammatory cytokines
(for example, IL-10) or by antagonizing their action at
the receptor level (for example, IL-1RA). In turn, the
actions of proinflammatory cytokines on peripheral
cellular targets, such as hepatocytes, lead to the synthe-
sis of acute phase proteins (for example, CRP) respon-
sible for the systemic inflammatory response. The link
between depression and inflammation was initially sug-
gested by clinical findings showing that depression is
accompanied by up-regulated inflammatory response,
such as an increased production of pro-inflammatory
cytokines and acute phase reactive proteins [73,74].
Systemic elevations of these molecules in the absence of
infection or tissue injury are considered abnormal and
increase the onset of, for example, cardiovascular dis-
ease, diabetes and mortality [75,76]. There is a strong
interconnection between metabolic abnormalities and
inflammation illustrated by the facts that abdominal fat
tissue produces cytokines and these, subsequently, in-
crease metabolic syndrome development [77,78].
Three recent meta-analyses reported significantly higher
levels of the inflammatory markers TNF-α, sIL-2R, IL-6
and IL-1RA in depressed subjects compared to controls
(see Table 2). Dowlati et al. [59] confirmed increased levels
of IL-6 and TNF-α among drug-naive MDD patients. Liu
et al. [60] recently extended this evidence to sIL-2R. For
IL-1β, no consistent significant association was found in
both meta-analyses [59,60]. Howren et al. [58] confirmed
the depression-inflammation association also in larger
population samples, many of which used depressive symp-
tom reports and most often studied IL-6 and CRP, a
nonspecific acute-phase protein synthesized in the liver in
response to cytokine stimulation. They confirmed stronger
associations - although still of modest effect size - with in-
flammatory markers for studies using clinical diagnoses of
depression than those using symptom reports. An essen-
tial role was found for body mass index (BMI) as a covari-
ate: studies adjusting for BMI found much lower effect
sizes, likely due to the fact that adipose tissue is an im-
portant source of cytokines. However, even after adjust-
ment for BMI, elevated inflammation levels in the
depressed were observed, indicating that immune and
metabolic dysregulations are partly complementary.
Most meta-analyzed studies were cross-sectional, which
makes it hard to draw any causal inferences. However,
several lines of research indicate that the link between in-
flammation and depression is likely bidirectional [79]. It
has been demonstrated that immunotherapy with IFN-α
can precipitate depression [80]. Cytokines produced per-
ipherally can access the brain directly by crossing the
blood–brain barrier through saturable active transport
systems, or via indirect pathways including activation of
microglia, diffusion into the brain through leukocytes in
the choroid plexus and circumventricular region, and
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proteins released by microglia [81]. Activated microglia
employ IL-6 and TNF-α as antineurogenic signals, which
can interact directly with neural progenitor cells via TNF
and IL-6 receptors causing a decrease in neurogenesis,
and also in emotion-regulating brain structures involved
in depression.
Another mechanism relating pro-inflammatory cyto-
kines to mood is their capacity to induce the indoleamine-
2,3-dioxygenase (IDO) enzyme, which catalyzes the
synthesis of kynurenine from dietary tryptophan [82]. This
may contribute to depressive symptoms by reducing the
availability of the requisite precursor (tryptophan deple-
tion) for the synthesis of serotonin and melatonin. Perhaps
even more importantly, IDO activation also increases the
synthesis of tryptophan catabolites (TRYCATs), such as
kynurenine, kynurenic acid and quinolinic acid. The latter
is an endogenous N-methyl-D-aspartate agonist that could
perturb neurotransmission along glutamatergic pathways
and may lead to hippocampal neuron damage and apop-
tosis which could contribute to depression symptoms
[83]. Some - but not all - studies confirmed higher
TRYCAT levels in depressed patients, especially those de-
pressed cases with physio-somatic symptoms [84] and
TRYCAT levels have been linked with cardiac dysfunction,
pain and other somatic health complaints (see Anderson
G et al. [85] for more detailed description).
Recent findings from clinical studies suggest that de-
pression is also associated with other immune-related
mechanisms, such as cell-mediated immunity and auto-
immune responses directed against cell structures altered
by oxidative and nitrosative stress. A detailed discussion
of these aspects goes beyond the scope of this review, but
has been recently summarized [81,86,87].
Pro-inflammatory cytokines have been shown to in-
duce stress-reactive neuroendocrine and central neuro-
transmitter changes reminiscent of those in depression
[79]. Inflammatory processes can influence central sero-
tonin availability also through increased uptake after
phosphorylation of the high-affinity serotonin trans-
porter via the activation of p38 mitogen-activated pro-
tein kinases [81]. Finally, as discussed above, fat mass
and its associated metabolic regulations are strongly
connected to inflammation. Nutrition overload causes
adipocytes to become hypertrophic and to secrete
chemo-attractant proteins, which lead to recruitment of
macrophages that produce their own pro-inflammatory
cytokines and chemokines, attracting additional macro-
phages and setting up a feed-forward inflammatory
process [66]. Depression may also facilitate weight gain -
partly as a result of sedentary behavior and unhealthy
dietary choice - which in turn promotes inflammation
that may ultimately reinforce depression, creating a dele-
terious vicious cycle for physical and mental health.Autonomic dysregulation
Acute stress results in immediate activation of sympa-
thetic nerves and reduction of parasympathetic nerves in
order to prepare the body for a fight or flight response. An
indication of autonomic activity can be obtained from
looking at catecholamine levels. Indeed, some older stud-
ies indicate a tendency for the urinary excretion of nor-
adrenaline and its metabolites to be diminished [88,89],
whereas other reports document elevated plasma levels of
noradrenaline [90]. A more direct way of measuring auto-
nomic tone is by measuring noradrenaline spillover to
plasma [91,92] in patients with MDD. A recent noradren-
aline spillover study among MDD patients by Barton et al.
[93] found sympathetic nervous activity to be high, includ-
ing the sympathetic outflow to the heart, but this was
restricted to only a subgroup of MDD patients.
Such invasive spillover studies are unfortunately not eas-
ily implementable in large psychiatric cohorts, restricting
our insights into generalizability of results and the role of
potential underlying confounding factors. That is why
many researchers have used non-invasive, but more indir-
ect indicators of autonomic tone, for example, obtained
from electrical and impedance cardiography assessments.
A non-invasive method for autonomic dysregulation as-
sessment is heart rate variability (HRV), particularly in the
respiratory frequency range, as an indicator of cardiac
vagal control. HRV reflects an individual’s capacity for
parasympathetic inhibition of autonomic arousal in emo-
tional expression and regulation, and is an important pre-
dictor for cardiovascular disease and mortality [94,95].
Depression is hypothesized to involve an autonomic ner-
vous system that is in a relative state of more sympathetic
and less parasympathetic activation. According to the
polyvagal theory, this is partly due to the fact that impair-
ments of low vagal tone are associated with reduced social
engagement and a less flexible behavioral response to en-
vironmental changes [96].
Rottenberg [61] summarized 13 studies including 312
depressed patients and 374 controls and found a signifi-
cantly reduced HRV in depression (Cohen’s d = 0.33, see
Table 2). Four years later, Kemp et al. [62] repeated a
meta-analysis in which only power-domain analyses
were allowed to measure HRV and all included subjects
were free of cardiovascular disease. Meta-analyzing re-
sults of 14 studies (302 patients, 424 controls) yielded a
significant pooled effect size indicating a lower HRV
among the depressed. Contrary to these results, was a
study by Licht et al. [97] with a sample size that was by
far larger than the total number of participants in the
meta-analyses, and could adjust for lifestyle. In this
study, 1,018 MDD patients without antidepressants and
515 controls did not consistently show differences in
HRV on all measures. Only on the respiratory sinus
arrhythmia indicator of HRV the depressed persons
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their two-year follow-up [98] it was confirmed that
MDD state (changes) were not associated with HRV. On
the contrary, significantly lower HRV was found among
MDD patients using antidepressant medication, espe-
cially tricyclic antidepressants (TCAs) and serotonergic-
noradrenergic reuptake inhibitors (SNRIs). This led to
the authors’ conclusion that it is not the depressed state
but the use of antidepressants that changes autonomic
tone. The TCA effect on HRV, likely through direct anti-
cholinergic effects, was recently confirmed in a meta-
analysis [62]. So it remains rather unclear whether
depression itself is associated with a reduced vagal tone.
Of note is that studies included in these meta-analyses
measured an autonomic tone during resting conditions.
Depression could be more strongly associated with re-
duced parasympathetic tone when persons are exposed
to stress conditions.
Sympathetic tone in depressed persons has been less
often examined on a large scale, and no meta-analysis is
available. Some small-scale studies reported increased
sympathetic activity in depressed subjects measured in-
directly by skin conductance responses, QT interval
variability or the pre-ejection period (PEP) [91,99-102],
although not consistently [103]. In contrast to invasive
norepinephrine spillover studies, the advantage of
assessing PEP, a thoracic impedance cardiography meas-
ure indexing changes in β-adrenergic inotropic drive to
the left ventricle, is that it can be obtained non-
invasively in large samples, thereby allowing greater
generalizability of results, and examination of potential
confounding factors. However, it should be noted that
PEP is an indirect sympathetic tone indicator since it
may also be influenced by changes in clearance, re-
uptake or adrenoceptor sensitivity. A recent large study
compared PEP among 1,093 MDD patients and 621 con-
trols [104]. Cross-sectional nor two-year longitudinal re-
sults could confirm a higher sympathetic tone in the
depressed. Again, antidepressant medication, especially
TCAs and to a lesser extent SNRIs, was associated with
increased sympathetic tone.
Overall, although some evidence points towards a
hypersympathetic/hypovagal state among depressed per-
sons, the evidence is not consistent and antidepressant
treatment appears to be a strong confounding factor.
Autonomic dysregulation is involved in cardiovascular
somatic symptoms, such as tachycardia, blood pressure
liability and tendencies toward hypertension. In a large
cohort study [105], lower HRV was associated with more
metabolic syndrome dysregulations, but not to HPA-axis
activity. Finally, sympathetic activation may have a role
in the stress-induced activation of the immune system as
catecholamines can trigger the inflammatory signaling
cascade [106].Hypothalamic-pituitary-adrenal (HPA) axis dysregulation
Hyperactivity of the HPA-axis in depression has been
considered one of the most reliable findings in biological
psychiatry. Chronic stress is perceived by the cortex of
the brain and transmitted to the hypothalamus, where
corticotropin-releasing hormone (CRH) is released onto
pituitary receptors, ultimately resulting in release of cor-
tisol into the blood [107]. To assess HPA-axis activity,
salivary measures are increasingly used to reflect the ac-
tive unbound form of cortisol. The cortisol awakening
response assesses the natural response of the HPA-axis
to awakening; evening cortisol levels reflect basal activ-
ity. Knorr et al. [64] meta-analyzed 20 case–control
studies including 1,354 depressed patients and 1,052
controls (Table 2). The average salivary cortisol level was
2.58 nmol/l increased in the morning and 0.27 nmol/l in
the evening for depressed patients. A recent study
among 701 current and 579 remitted depressed cases
found that both groups had higher cortisol awakening
response and evening levels as compared to 308 healthy
controls [108], suggesting that HPA-axis hyperactivity
represents more a vulnerability than a state indicator. In
line with this, HPA-axis hyperactivity has also been
observed among non-affected offspring of depressed pa-
tients, suggesting that it may partly reflect a genetic vul-
nerability marker or endophenotype of depression [109].
In an even larger meta-analysis by Stetler and Miller
[63], evidence for higher cortisol levels across various
bodily fluids was summarized. Again, this evidence illus-
trated that depressed individuals displayed increased
cortisol levels (d = 0.60), although the effect size was
considerably less - and only modest when only high
methodological quality studies were included (d = 0.33).
Effect sizes were higher for cortisol levels determined in
plasma or urine than for those in saliva. The authors
also meta-analyzed other HPA-axis indicators and found
elevated levels of adrenocorticotropin hormone (ACTH)
among the depressed (d = 0.28), but no elevation in
CRH (d = 0.02).
Some studies used a dexamethasone test to evaluate
the sensitivity of the hypothalamus to feedback signals
for the shutdown of CRH release. No meta-analysis has
compared dexamethasone suppression across regular de-
pressed cases and controls. Nelson et al. [110] described
that dexamethasone-suppression studies found that the
normal cortisol-suppression response is absent in about
half of the patients with very severe symptoms (for ex-
ample, those hospitalized or those with psychotic symp-
toms). The non-suppression rate in outpatients with
major depression was found to be much lower. A recent
large-scale study did not find a different cortisol re-
sponse after dexamethasone (0.5 mg) suppression in
1,280 MDD outpatients versus controls [108]. So, the
indicated larger non-suppression of the HPA-axis in
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(psychotic) cases.
Several mechanisms may underlie the relationship be-
tween HPA-axis dysregulation and depression. Although
hypercortisolism may be related to alterations at any
level of the HPA-axis, research in depression focused on
the role of mineralocorticoid (MR) and glucocorticoid
(GR) receptors, acting as transcriptional regulators of
cortisol effects on the initiation and termination of the
stress response [111]. Both types of receptor are abun-
dantly expressed in neurons of limbic regions but have
different affinity to cortisol (approximately 10-fold
higher for MR that is heavily occupied by basal gluco-
corticoids levels, while GR is only heavily occupied dur-
ing stress) and different transcriptional activity. MR is
implicated in the appraisal process that triggers the
stress response, while GR is part of a negative feedback
aimed at normalizing HPA-axis output. Alterations of
this regulating network, defined glucocorticoid resist-
ance, may determine a chronic activation of the stress
response resulting in atrophy of hippocampal cells, re-
duced neurogenesis and synaptic plasticity and altered
monoaminergic signaling, all of which may lead to a de-
pressive state [111]. Other factors may be involved in
the dysregulation of HPA-axis responsiveness, including
early-life epigenetic programming of GR genes and in-
flammatory processes [112]. A wide range of studies
showed that pro-inflammatory cytokines may promote the
release of CRH, ACTH and cortisol by acting directly on
hypothalamic and pituitary cells and disrupting GR func-
tion leading to glucocorticoid resistance [112,113].
Heterogeneity of depression: the role of symptom
profiles
All meta-analyses described in Table 2 indicated in gen-
eral a modest effect size and a considerable amount of
heterogeneity in biological dysregulations among de-
pressed persons. Such variability could be attributable to
sampling (for example, clinical sample vs. community),
sample composition (for example, age and ethnic com-
position) or methodological differences in depression
and biological measures. However, variability could also
be due to heterogeneity of depression. There is general
consensus that clinical heterogeneity hinders efforts to
identify biologic, genetic and environmental underpin-
nings of depression. In fact, the lack of genetic markers
associated with MDD in the largest collaborative genetic
study was interpreted to be largely attributable to its
widespread heterogeneity [114]. It is crucial that depres-
sive subtypes constituting more homogeneous pheno-
types are taken into account in research and that
in-depth studies of biological correlates of depressive
subtypes are conducted in order to bring the psychi-
atric field forward.The current Diagnostic and Statistical Manual of Men-
tal Disorders (DSM) classification includes three speci-
fiers of symptom characteristics during depressive
episodes: catatonic, melancholic and atypical features.
Most outpatient and community studies focus on melan-
cholic and atypical subtypes because of the low fre-
quency of catatonia. Atypical depression is marked by
hypersomnia and fatigue, increased appetite and weight
gain, mood reactivity and interpersonal rejection sensi-
tivity. Unlike its name suggests, it is present in approxi-
mately 15% to 30% of depressed cases [115,116].
Melancholic depression is characterized by a disturbance
in affect marked by anhedonia and non-reactive mood,
by psychomotor disturbance and by vegetative and cog-
nitive symptoms of insomnia, loss of appetite and
weight, diurnal mood variation and impaired concentra-
tion. Approximately 25 to 30% of depressed individuals
display melancholic features [115]. Criteria for subtypes
were originally established based on clinical observa-
tions, but it should be noted that not all core criteria of
these subtype definitions have been justified through
research. In fact, some of the core characteristics of the
atypical subtype have received increased scrutiny by
research showing that the cardinal symptom of mood
reactivity is not associated with the other subtype symp-
toms [117,118], and the interpersonal rejection sensitiv-
ity may be more a personality trait than a symptom
[119]. Nevertheless, recent data-driven techniques exam-
ining a wide range of depressive symptoms have con-
firmed that depressed populations can generally be
divided into a melancholic (sometimes termed ‘typical’)
and an atypical subtype which are not very different in
overall severity but differentiate mainly in terms of appe-
tite, weight and sleep symptoms (more in atypical, less
in melancholic depression) [115,116,120-122] and to a
lesser extent in terms of feelings of worthlessness, guilt
and suicidal ideation (more in melancholic depression)
[115]. Distinction in these subtypes is rather stable over
time, as pointed out in a recent longitudinal study
among chronic patients [116]; of persons with atypical
depression at baseline, 79% still had the atypical subtype
after two years, which was 70% in those with melan-
cholic depression.
Increasing evidence suggests that melancholic and atypical
depressive subtypes contribute to variability in associations
with biological measures. Table 3 lists studies examining this
issue. Comparing melancholic depressed versus non-
melancholic depressed persons, Seppälä et al. [53] found
metabolic syndrome to be increased in those with atypical
depression but not in melancholic depression. In line with
this, when directly comparing 319 melancholic versus 201
atypical depressed patients, Lamers et al. [115] found meta-
bolic syndrome and, in particular, its obesity-related distur-
bances to be more present in atypical depression.
Table 3 Overview of studies comparing biological dysregulations across melancholic and atypical depression








Lamers et al. 2010 [115] 379 201 - AD more MetS than MD
Seppala et al. 2012 [53] 293 1391 2,388 AD more MetS than C, no association with MD
Immuno-inflammatory dysregulation
Anisman et al. 1999 [123] 17 31 27 No difference in IL-1b + IL-2
Kaestner et al. 2005 [124] 21 161 37 AD higher IL-1b + IL-1RA than C + MD
Huang et al. 2007 [125] 25 171 40 MD higher IL-1b than AD no difference in IL-10 and
TNF-α
Yoon et al. 2012 [126] 70 35 - AD higher IL-2 and lower IL-4 than MD no differences
in IL-6 + TNF-α
Lamers et al. 2012 [127] 111 122 543 AD higher IL-6 + CRP + TNF-α than MD + C
Karlovic et al. 2012 [128] 32 23 18 MD + AD higher IL-6 + CRP than C no difference in
TNF-α
HPA-axis dysregulation
Nelson et al. 1997 [110] 662 6171 - MD more DST non-suppression than AD
Anisman et al. 1999 [123] 17 31 27 AD lower cortisol than C
Wong et al. 2000 [129] 10 - 14 MD higher cortisol than C
Kaestner et al. 2005 [124] 21 161 37 MD higher cortisol than AD + C
Lamers et al. 2012 [127] 66 82 393 MD higher cortisol than AD + C
Karlovic et al. 2012 [128] 32 23 18 MD higher cortisol than AD + C
1 Atypical depression was assessed as the absence of melancholic depression (non-melancholic depression).
AD, Atypical depression; C, Healthy controls; CRP, C-reactive protein; DST, Dexamethasone suppression test; IL, Interleukin; MD, Melancholic depression; MetS,
Metabolic syndrome; TNF, Tumor necrosis factor.
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tion levels among atypical depression (see Table 3).
Kaestner et al. [124] observed higher levels of IL-1β and
IL-1RA in non-melancholic patients than in melan-
cholics and controls. Also Yoon et al. [126] found higher
IL-2 and lower IL-4 in atypical depression than in mel-
ancholic depression. On the contrary, other studies
found higher IL-1β in persons with melancholic features
than in those without, or found no inflammation differ-
ences between melancholic and atypical depression
groups [123,125,128]. The largest study to date recently
compared 111 chronic melancholic depressed cases ver-
sus 122 chronic atypical depressed cases and confirmed
higher levels of IL-6, TNF-α and CRP in atypical depres-
sion as compared to both melancholic depression and
healthy controls [127]. Overall, evidence seems to be
emerging that metabolic and, to some extent also, in-
flammation dysregulations are more advanced in atypical
than in melancholic depressed subjects.
The picture is quite different for hypercortisolemia.
Table 3 illustrates that several studies directly comparing
cortisol levels across melancholic and atypical depression
point out that hypercortisolemia is more often observed
in melancholic depression [124,127-129]. Cortisol levels
among individuals with atypical depression may not be
reliably higher than cortisol levels among healthy non-depressed persons. Some studies [123,127] even suggest
a relative hypocortisolism in atypical depression. Find-
ings in Table 3 are in line with a sub-analysis in Stetler
and Miller’s meta-analysis [63] in which the effect size of
the cortisol-depression association is higher when more
melancholic depressed cases were included in studies,
and lower when more atypical depressed cases were in-
cluded. Melancholic features were associated with 54%
larger effect sizes compared with depression without
melancholic features.
Although some studies suggested differences in auto-
nomic tone dysregulation depending on specific depres-
sion symptoms [61,130,131], no studies directly compared
autonomic tone dysregulation between melancholic versus
atypical depression. In all, research into the specificity of
the association of biological dysregulations to specific
depression subtypes has just begun. Its findings seem to
suggest that metabolic and inflammation dysregulations
may be more involved in atypical depression, whereas
hypercortisolemia appears more specific for melancholic
depression. Consequently, not considering the heterogen-
eity of depression in pathophysiological research may con-
tribute to blurred effect sizes. That metabolic syndrome
and potentially also inflammation dysregulations cluster in
atypical depression cases is understandable from the tight
associations among appetite, fat mass, dyslipidemia and
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ical depression, and a higher BMI has been observed
among atypical versus melancholic depressed patients
[115]. These mechanisms may not be as strongly related
to HPA-axis hyperactivity. Although the HPA-axis in nor-
mal situations tempers inflammatory reactions, prolonged
hyperactivity could result in blunted anti-inflammatory
responses to glucocorticoids resulting in increased inflam-
mation [132,133]. However, the relationship between
HPA-activation and its effect on inflammation is ex-
tremely complex; whether glucocorticoids increase or de-
crease inflammation may depend on factors such as dose,
duration and timing of glucocorticoids exposure and the
brain area involved [134]. Animal models show that GR
activation during chronic stress increases lipopolysacchar-
ide (LPS)-induced nuclear factor kappa B (NFkB) activa-
tion and TNF-α and IL-1β expression in the hippocampus
and frontal cortex, but has opposite effects in the hypo-
thalamus [135]. Furthermore, communication between
these systems could also be hampered after prolonged
dysregulation of one of the stress systems. This may ex-
plain that the HPA-axis and the inflammation/metabolic
stress systems operate more independently of each other,
and their activities can be differentially linked to different
depression subtypes. In line with this, in a cohort of 2,900
subjects, we confirmed strong intercorrelations between
the autonomic nervous system and metabolic syndrome
indicators but no significant association between these
systems with HPA-axis functioning [105].
Therapeutic implications for biological dysregulation in
depression
Do antidepressant treatments reduce biological dys-
regulations in depression? And if a different pathophysi-
ology exists across depressive subtypes, does this suggest
differential effective treatment strategies across sub-
types? These are adequate questions that so far have
only been partly addressed. We will briefly summarize
what is currently known in this research area.
Regarding inflammatory and metabolic dysregulations,
an observational cohort study among over 1,000 MDD
patients found that, independent of potential differences
in severity, TCA users had more metabolic and inflam-
matory dysregulations than medication-naïve depressed
persons [30,136]. In contrast, selective serotonin re-
uptake inhibitor (SSRI) users had slightly lower inflam-
matory levels than non-medicated depressed patients
[136]. Also others found inflammatory and metabolic
dysregulations to be more prominent in persons using
SNRI, TCA or tetracyclic antidepressants (TeCA)
[39,137], whereas beneficial inflammatory profiles were
present in SSRI users [106]. In line with this, two meta-
analyses showed that SSRI treatment, but not other
types of antidepressants, reduced inflammatory levels[138,139]. In vitro studies [140] demonstrate that admin-
istration of SSRIs produces anti-inflammatory effects in
blood of both people with depression and healthy volun-
teers through their effects on increasing intracellular cyclic
adenosyl monophosphate, serotonin metabolism or direct
action on neurogenesis [141]. On the contrary, TCAs could
result in slightly more metabolic dysregulation since its
antihistaminergic and adrenergic effects may induce weight
gain and subsequent dyslipidemia and hypertension
[142,143]. Also, both longitudinal observational studies
[98,102,104] and a meta-analysis [62] observed increased
sympathetic activation and reduced parasympathetic acti-
vation among TCA users. The anticholinergic effects of
TCAs, and potentially also SNRIs, increase circulating nor-
epinephrine levels, also in the sinoatrial node and left ven-
tricle [144], thereby directly affecting contractility and
heart rate. In contrast, SSRIs do not exert such an effect
but instead reduce the firing rate in the noradrenergic
locus coeruleus [145] involved in generating cardiac sym-
pathetic activity [146]. Consequently, the different effects
of antidepressant medication classes on cardiac sympa-
thetic effects appear to have a plausible biological basis,
and deserve attention in clinical practice as these effects
have shown impact on clinically relevant outcomes, such
as hypertension [143].
Whether standard antidepressant treatments improve
HPA-axis hyperactivity has not been often addressed.
Since this hyperactivity has been observed among remit-
ted depressed patients [108], and non-affected offspring
of depressed patients [109], it may be more a vulnerabil-
ity than a state characteristic. Nevertheless, some
evidence suggests that at least a subgroup of depressed
patients shows improved HPA-axis regulation, for
example, as indicated by a decreased DEX-CRH test
response, after a two-week antidepressant treatment
period which was subsequently associated with beneficial
treatment response [147].
Not only can antidepressants impact on biological
dysregulation, dysregulation can also impact on the efficacy
of antidepressants. A few recent studies provide evidence
for this. A study of 24 MDD inpatients showed that higher
IL-6 levels predict non-response to a six-week treatment
with amitriptyline, while TNF-α levels were high in both
responders and non-responders, but only decreased during
treatment in responders [148]. In another study among
100 depressed patients, higher TNF-α levels predicted
non-response to a 12-week treatment with escitalopram
[149]. Poor treatment response could be the result of in-
flammatory and metabolic dysregulation having direct
negative effects on the monoamine system, such as in-
creasing the activity of monoamine transporters [150] and
reducing monoamine precursors [151] and monoamine
biosynthesis, [152] which counterbalance effects of anti-
depressant medication.
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terventions? Some recent evidence suggests that add-on
anti-inflammatory agents may be useful in clinical de-
pression management. In a placebo-controlled trial of 60
treatment-resistant MDD patients, Raison et al. [153]
found a TNF-α antagonist to reduce depressive symp-
toms in persons with high baseline inflammatory
markers. Furthermore, behavioral interventions, such as
exercise, were able to normalize immune and metabolic
dysregulation [154] and improve mood to some degree
[155], and might, therefore, be an indicated treatment
especially for the depressed subgroup with inflammatory
and metabolic dysregulation. This idea is supported by a
recent study showing that exercise treatment appeared
to be more effective in reducing depressive symptoms
among patients with high baseline levels of TNF-α [156].
However, at this moment, these considerations for treat-
ment implications are still largely speculative and should
be confirmed in longitudinal and experimental studies.
A recent study did not find larger efficacy of SSRIs or
TCAs in melancholic versus atypical depression [157].
Since this review illustrated more metabolic and, al-
though less consistently, inflammatory dysregulations in
atypical depression, it should be explored whether, for
example, add-on anti-inflammatory agents or alternative
treatment regimen, such as exercise, are more beneficial
to this depression subgroup.
Conclusions
This review summarized longitudinal evidence indicating
that depression increased the onset risk of a multitude of
somatic disorders including, for example, cardiovascular,
stroke, diabetes and obesity morbidity. These somatic con-
sequences may partly be due to biological dysregulation
present among depressed patients. Less consistent obser-
vations are for autonomic dysregulation among depressed
patients. However, metabolic dysregulation involving
mainly abdominal obesity and dyslipidemia, and poten-
tially also inflammatory dysregulation, appear more often
present among depressed persons, especially among those
with atypical depression features. Hyperactivity of the
HPA-axis has also been observed, but most consistently
among depressed patients with melancholic features.
These observations suggest that not considering the het-
erogeneity of depression in pathophysiological research
may contribute to blurred effect sizes. Consequently,
pathophysiological distinction across depressive subtypes
deserves further attention in future research. In addition,
other recently indicated physiological mechanisms that
could underlie the link between depression and somatic
morbidity, such as the oxidative and nitrosative stress
(O&NS) pathways [86], deserve further research. Future
research needs to examine to which extent existing and
new antidepressant interventions can reduce biologicaldysregulation thereby improving the vicious cycle in
which depression and somatic ill-health interact.
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